Lunesta - Special Populations
Hepatic
The starting dose of LUNESTA should be 1 mg in patients with severe hepatic impairment.
LUNESTA should be used with caution in these patients.
Coadministration With CYP3A4 Inhibitors
The starting dose of LUNESTA should not exceed 1 mg in patients coadministered LUNESTA with potent CYP3A4 inhibitors. If needed, the dose can be raised to 2 mg.
HOW SUPPLIED:
LUNESTA 3 mg tablets are round, dark blue, film-coated, and identified with debossed markings of S193 on one side, and are supplied as:
NDC 63402-193-10 - bottle of 100 tablets
NDC 63402-193-09 - carton of 90 tablets
LUNESTA 2 mg tablets are round, white, film-coated, and identified with debossed markings of S191 on one side, and are supplied as:
NDC 63402-191-10 - bottle of 100 tablets
NDC 63402-191-09 - carton of 90 tablets
LUNESTA 1 mg tablets are round, light blue, film-coated, and identified with debossed markings of S190 on one side, and are supplied as:
NDC 63402-190-10 - bottle of 100 tablets
Store at 25˚C (77˚F); excursions permitted to 15˚C to 30˚C (59˚F to 86˚F).
Manufactured for:
Sepracor Inc.
Marlborough, MA 01752 USA
by Patheon Inc., Mississauga, Ontario L5N 7K9 Canada
For customer service, call 1-888-394-7377.
To report adverse events, call 1-877-737-7226.
For medical information, call 1-800-739-0565.
December 2004
NNNNNN
PHARMACIST - DETACH HERE AND GIVE INFORMATION TO PATIENT.
Related entries
Syndicate
|
